Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-18), the Forward Annual Dividend Yield of Farmaceutica Remedia is 5.75%.
As of today (2026-07-18), the Trailing Annual Dividend Yield of Farmaceutica Remedia is 4.60%.
BSE:RMAH's Forward Dividend Yield % is ranked better than 86.36% of 66
companies
in the Medical Distribution industry
Industry Median: 2.865
vs BSE:RMAH: 5.75
During the past 12 months, Farmaceutica Remedia's average Dividends Per Share Growth Rate was -20.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -7.20% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 0.50% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Farmaceutica Remedia was 146.60% per year. The lowest was -30.70% per year. And the median was -7.20% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Farmaceutica Remedia Forward Dividend Yield % Related Terms
BSE:RMAH vs MCK, CAH, COR: Forward Dividend Yield % Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Forward Dividend Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Farmaceutica Remedia Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
RON 0.040000
2025-09-11
2025-09-12
2025-09-30
Cash Dividend
annually
RON:RON 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Farmaceutica Remedia's Forward Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 5.75% mean?
Farmaceutica Remedia (BSE:RMAH) has a Forward Dividend Yield % of 5.75% as of Jul. 18, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Farmaceutica Remedia and its competitors. According to the industry distribution chart, Farmaceutica Remedia ranks #9 out of 66 companies in the Medical Distribution industry, placing it in the top 13.6%.
Is Farmaceutica Remedia's Forward Dividend Yield % too high?
Farmaceutica Remedia's current Forward Dividend Yield % is 5.75%. The Medical Distribution industry median Forward Dividend Yield % is 2.87. Farmaceutica Remedia's value of 5.75% is 100.7% above this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #9 out of 66 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Forward Dividend Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #9 out of 66 companies for Forward Dividend Yield %. This places Farmaceutica Remedia in the top 14% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 2.87. Farmaceutica Remedia's value of 5.75% is 100.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Distribution company?
The median Forward Dividend Yield % among Medical Distribution companies is 2.87, based on 66 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current Forward Dividend Yield % of 5.75% is 100.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median Forward Dividend Yield % is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current Forward Dividend Yield % is 5.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current Forward Dividend Yield % is 5.75% and 100.7% above the Medical Distribution industry median of 2.87. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Forward Dividend Yield % is 5.75% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79.
GuruFocus considers Farmaceutica Remedia to be Fairly Valued.
Key valuation signals for BSE:RMAH:
Forward Dividend Yield %: 5.75%
GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
Industry Position: 100.7% above the Medical Distribution median (#9 of 66)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for BSE:RMAH
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
